Idarubicin versus Epirubicin in Transarterial Chemoembolization for Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma: An Open-label, Randomized, Phase IV Trial
Radiology · 01.05.2025 · 315 (2)
DOI: 10.1148/radiol.242315 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Radiology, erschienen am 01.05.2025. Verfasst von Haikuan Liu und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interventional Oncology, The First Affiliated Hospital of Sun Yat-Sen University No.58 Zhongshan 2nd Rd, Guangzhou 510080, China. Hauptthemen laut MEDLINE: Epirubicin, Idarubicin, Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Compared with epirubicin, idarubicin increased survival rates in participants with Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma undergoing drug-eluting bead transarterial chemoembolization without an increase adverse event incidence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Interventional Oncology, The First Affiliated Hospital of Sun Yat-Sen University No.58 Zhongshan 2nd Rd, Guangzhou 510080, China.
- Department of Tumor Minimally Invasive, Taian City Central Hospital, Taian, China.
- Department of Interventional Oncology, Jinshazhou Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
- Department of Hepatobiliary Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, China.
- Department of Interventional Radiology, Guangdong Province Hospital-Zhuhai Hospital, Zhuhai, China.
ORCID-Profile: Haikuan Liu, Wenzhe Fan, Liangliang Qiao, Zhilong Liu, Bowen Zhu, Yiyang Tang, Miao Xue, Yanqin Wu, Yue Zhao, Yang Jiang, Kangshou Liu, Junjie Liang, Mingrong Cao, Jiaping Li
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Liu, H., Fan, W., Li, H., Qiao, L., Liu, Z., Zhu, B., Guo, J., Huang, K., Tang, Y., Wen, J., Xue, M., Wu, Y., Zhao, Y., Jiang, Y., Liu, K., Liang, J., Cao, M., & Li, J. (2025). Idarubicin versus Epirubicin in Transarterial Chemoembolization for Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma: An Open-label, Randomized, Phase IV Trial. Radiology, 315(2). https://doi.org/10.1148/radiol.242315
Vancouver
Liu H, Fan W, Li H, Qiao L, Liu Z, Zhu B, et al. Idarubicin versus Epirubicin in Transarterial Chemoembolization for Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma: An Open-label, Randomized, Phase IV Trial. Radiology. 2025;315(2). doi:10.1148/radiol.242315
BibTeX
@article{Liu2025,
author = {Liu, Haikuan and Fan, Wenzhe and Li, Haiqing and Qiao, Liangliang and Liu, Zhilong and Zhu, Bowen and Guo, Jian and Huang, Kun and Tang, Yiyang and Wen, Jie and Xue, Miao and Wu, Yanqin and Zhao, Yue and Jiang, Yang and Liu, Kangshou and Liang, Junjie and Cao, Mingrong and Li, Jiaping},
title = {Idarubicin versus Epirubicin in Transarterial Chemoembolization for Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma: An Open-label, Randomized, Phase IV Trial},
journal = {Radiology},
year = {2025},
volume = {315},
number = {2},
doi = {10.1148/radiol.242315}
}
EUVIMED